RPG Life Sciences Partners with Archerchem Healthcare for Naprosyn ES Launch in India
RPG Life Sciences (RPG LS) has partnered with Archerchem Healthcare to exclusively market and distribute Naprosyn ES across India. The partnership involves launching the combination of Naproxen and Esomeprazole, offering a differentiated anti-inflammatory solution combined with gastroprotection for the first time in the country.Naprosyn ES is marketed as a combination medicine designed to provide effective relief from inflammation while mitigating risks to the digestive system. This product was co-developed by Archerchem Healthcare alongside its development partner. RPG LS will be responsible for the exclusive marketing and distribution of Naprosyn ES, with Archerchem serving as the exclusive supplier.
The launch addresses a critical unmet need among patients who require long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, especially those who are susceptible to gastrointestinal complications. The differentiated formulation is intended to improve patient compliance and enable safer long-term pain management, particularly for elderly and gastro-sensitive populations.
Ashok Nair, Managing Director of RPG Life Sciences, commented on the development, stating that innovation at RPG Life Sciences is rooted in patient centricity. He noted that Naprosyn ES exemplifies their R&D-driven approach to differentiated products, highlighting the long-standing trust that doctors and patients place in the Naprosyn brand.
Anil Dhedia, Chairman & Managing Director of Archerchem Healthcare, added that this partnership showcases Archerchem's core capability in developing complex differential formulations. He stated that through the collaboration with RPG Life Sciences, a pharmaceutical company possessing a strong presence across chronic and acute therapies including pain management, they are proud to deliver incremental innovation that enhances medication adherence and brings significant benefit to patients nationwide.
RPG Life Sciences intends to leverage the established brand recognition of Naprosyn and utilize its comprehensive pan-India distribution network and reach among super-specialists to drive the product's market penetration. The introduction of Naprosyn ES aligns with RPG Life Sciences’ commitment to building a differentiated portfolio within chronic therapy segments.
Naprosyn ES is currently available across India.
RPGLIFE Stock Price Movement
At 12:38 PM, RPG Life Sciences Limited sheds ₹13.40, with shares sliding 0.47% to trade at ₹2843.5. The equity is trading within its current range, remaining below the stock's yearly peak of ₹2956 while seeing a volume of 43,342 shares today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.